(Finance) – BioNTecha German biotechnology and biopharmaceutical company that developed together with Pfizer a vaccine for Covid-19, he recorded total revenue equal to 3,461.2 million euros for i three months ended September 30, 2022 (third quarter 2021: € 6,087.3 million). “As expected, the course of the pandemic remains dynamic and has led to fluctuations in quarterly revenues,” the company said. For the nine months ended September 30, 2022total revenues were 13,032.3 million euros (9 months 2021: 13,444.2 million euros).
L’Net income was 1,784.9 million euros, in drop of 44% compared to 3,211 million euros in the same period last year. For the nine months, the net profit was € 7,155.7 million (9 months 2021: € 7,126.3 million).
“Thanks to our strong execution in the third quarter of 2022, we have updated our COVID-19 vaccine revenue guidance for the year 2022 to the upper end of the original range,” he said. Jens Holstein, CFO by BioNTech We have started shipments of our bivalent vaccines adapted to Omicron at the beginning of September and we plan to continue with our deliveries throughout the fourth quarter of 2022 “.
BioNTech brought the estimated COVID-19 vaccine revenue for the full year at the upper end of the original range: € 16-17 billion (previously: € 13-17 billion). In any case, this would be a decrease compared to the 19 billion euros of revenues of last year.
(Photo: EPA / Biontech)